[vc_row el_class="mootsuit" css=".vc_custom_1472923750027{margin-bottom: -24px !important;}"][vc_column width="2/3"][vc_empty_space height="52px"][vc_custom_heading text="Join Our Members List For Exclusive Reports" font_container="tag:h1|text_align:center|color:%23000000" use_theme_fonts="yes"][/vc_column][vc_column width="1/3"][vc_empty_space height="16px"]





[/vc_column][/vc_row]

Uploaded by WesternUniversity
December 16, 2011

The first and only preventative HIV vaccine based on a genetically-modified, “killed whole” virus has received approval by the Food and Drug Administration to start human clinical trials. Tests have shown that the vaccine causes the body to produce antibodies to the HIV virus and to prevent infection from the virus.

Developed by Dr. Chil-Yong Kang and his team at The University of Western Ontario, with the support of Sumagen Canada, the vaccine (SAV001) holds tremendous promise, having already proven to stimulate strong immune responses in preliminary toxicology tests with no adverse effects or safety risks. It is one of only a few HIV vaccines in the world.

Interpreting Your Genetics Summit

Alexandra Bruce

View all posts

Add comment

Your email address will not be published. Required fields are marked *

Most Viewed Posts

Categories